The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 11, 2025

Filed:

Aug. 05, 2021
Applicants:

The Translational Genomics Research Institute, Phoenix, AZ (US);

Arizona Board of Regents on Behalf of Northern Arizona University, Flagstaff, AZ (US);

Inventors:

John Altin, Flagstaff, AZ (US);

Jason Ladner, Flagstaff, AZ (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
G01N 33/569 (2006.01); A61K 31/18 (2006.01); A61K 31/22 (2006.01); A61K 31/40 (2006.01); A61K 31/7052 (2006.01); A61K 39/215 (2006.01); A61P 11/00 (2006.01); C12N 7/00 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
G01N 33/56983 (2013.01); A61K 31/18 (2013.01); A61K 31/22 (2013.01); A61K 31/40 (2013.01); A61K 31/7052 (2013.01); A61K 39/215 (2013.01); A61P 11/00 (2018.01); C12N 7/00 (2013.01); G01N 33/6884 (2013.01); C12N 2770/20034 (2013.01); G01N 2333/165 (2013.01); G01N 2800/12 (2013.01); G01N 2800/245 (2013.01); G01N 2800/50 (2013.01);
Abstract

The present disclosure includes a multiplexed peptide assay to generate an epitope-resolved view of antibody reactivity across all human coronaviruses (CoVs). PepSeq accurately classifies SARS-CoV-2 exposure status and reveals epitopes across the Spike and Nucleocapsid proteins. Two of these represent recurrent reactivities to conserved, functionally-important sites in the S2 subunit of Spike, regions that we show are also targeted for the endemic CoVs in pre-pandemic controls. At one of these sites, we demonstrate that the SARS-CoV-2 response strongly and recurrently cross-reacts with the endemic virus hCoV-OC43. The disclosed epitope-resolved analysis reveals new CoV targets for the development of diagnostics, vaccines and therapeutics, including a site that may have broad neutralizing potential.


Find Patent Forward Citations

Loading…